Panacea Biotec achieved a significant turnaround in its March 2026 quarterly performance, reporting a consolidated net profit of ₹0.52 crore compared to a net loss of ₹1.89 crore in the corresponding quarter of the previous year. According to latest reports, this represents a complete reversal of the company's quarterly financial position. The company's operating profit margin (OPM) improved to 1.54% in Q4 FY26 from a negative 20.28% in Q4 FY25, indicating better operational efficiency. The earnings per share (EPS) for Q4 FY26 stood at ₹0.08 compared to a negative ₹0.31 in Q4 FY25, showing substantial improvement in profitability metrics.
The company demonstrated strong revenue growth with total income rising 19.97% to ₹169.30 crore in Q4 FY26 compared to ₹141.12 crore in Q4 FY25. As reported by latest financial data, this substantial increase in top-line revenue contributed significantly to the company's improved profitability. The profit before tax (PBT) turned positive at ₹86 crore in Q4 FY26 versus a loss of ₹26.87 crore in the previous year, while profit before depreciation and tax (PBDT) was ₹3.92 crore compared to a loss of ₹19.33 crore in Q4 FY25. The company also showed sequential growth with total income increasing 1.09% from ₹167.47 crore in Q3 FY26.
For the full financial year ended March 2026, Panacea Biotec reported a net loss of ₹5.37 crore compared to a net loss of ₹8.37 crore in the previous year, representing a 36% improvement in annual performance. According to latest financial data, total income for FY26 grew 13.27% to ₹656.67 crore from ₹579.75 crore in FY25. The company's operating profit margin for the full year improved to -0.73% from a negative 4.63% in the previous year, indicating gradual operational recovery throughout the fiscal year. EPS for FY26 was ₹-0.88 compared to ₹-1.37 in FY25, showing consistent improvement in earnings per share metrics.
Shares of Panacea Biotec Limited were trading at ₹412.40 on BSE as of the latest trading session, compared to the previous close of ₹413.50. The stock demonstrated active trading with 7,865 shares traded across 426 trades during the day, showing healthy market participation. The stock hit an intraday high of ₹426.90 and an intraday low of ₹408.70, indicating volatile but positive sentiment among investors. The net turnover during the trading session was ₹32.88 lakh, reflecting significant investor interest in the company's turnaround story.
